SCHEMBL2514765

SCHEMBL2514765

NOP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1O

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.75
P2RY1 P47900 7/20 0.71
ENPP1 P22413 3/20 0.71
P2RY2 P41231 2/20 0.65
P2RX1 P51575 2/20 0.65
P2RX3 P56373 2/20 0.65
P2RX2 Q9UBL9 2/20 0.65
SRC P12931 1/20 0.65
P2RX4 Q99571 1/20 0.65
ALDH1A1 P00352 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
DTYMK P23919 4/20 0.64
MACROD2 A1Z1Q3 1/20 0.61
SIRT6 Q8N6T7 1/20 0.61
MACROD1 Q9BQ69 1/20 0.61
TRPM2 O94759 1/20 0.61
PARG Q86W56 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3030614 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL78250 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL29702495 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL18785117 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL29350133 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL14471000 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL889289 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL5044161 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL703733 0.94 POLB (0.80) POLBP2RY1ENPP1P2RY2P2RX1
SCHEMBL2508784 0.94 POLB (0.81) POLBP2RY1ENPP1P2RY2P2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1970445-B1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS RIKEN (JP) 2012-09-26 EP disclosed
US-8030478-B2 Method for nucleic acid replication and novel artificial base pairs RIKEN (JP) 2011-10-04 US disclosed
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS RIKEN (JP) 2010-02-11 US disclosed
EP-1970445-A1 METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS Riken (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100036111-A1 METHOD FOR REPLICATING NUCLEIC ACIDS AND NOVEL UNNATURAL BASE PAIRS POLM, POLL, POLRMT POLB 8/4885P2RY1 1989/4885ENPP1 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.